<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303627</url>
  </required_header>
  <id_info>
    <org_study_id>DiskapiTRH</org_study_id>
    <nct_id>NCT01303627</nct_id>
  </id_info>
  <brief_title>Safety of Remifentanil Infusion</brief_title>
  <official_title>The Effects of Maintenance a Remifentanil Infusion on the Hemodynamic Variables and Recovery Quality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diskapi Teaching and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diskapi Teaching and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of maintenance remifentanil infusion with target controlled infusion during
      laryngeal mask airway removal on hemodynamic parameters and emergence quality is going to be
      investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In all patients (control group and remifentanil group induction of anesthesia will be
      achieved with desflurane and remifentanil.Anesthesia will be maintained with remifentanil
      (1-4 ng/mL) by TCI target controlled infusion, and desflurane . Throughout the surgery
      hemodynamic parameters are going to be recorded. As soon as the surgery has been finished, in
      control group remifentanil infusion and desflurane inhalation is going to be stopped.In
      remifentanil group,desflurane inhalation is going to be stopped and remifentanil infusion
      will be maintained until the removal of LMA. During the emergence period the time of eye
      opening, hemodynamic parameters and emergence quality (score 1-2)are going to be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Smooth cLMA Removal Condition (Score 1)</measure>
    <time_frame>At the end of the surgery</time_frame>
    <description>cLMA removal was accepted as successful (score 1) if none of the complications coughing, teeth clenching, gross purposeful movements, breath holding, laryngospasm, and desatura- tion to SpO2\90% was observed. If any of these compli- cations was observed it was regarded as unsuccessful (score 2)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Urinary Tract Problem</condition>
  <arm_group>
    <arm_group_label>ultiva,remifentanil,opioid,analgesic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remifentanil:1.5ng/ml remifentanil infusion maintained at the end of the surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control:Remifentanil stopped at the end of the surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>remifentanil</intervention_name>
    <description>1-4 ng/mL i.v. infusion during the surgery, maintenance dosage till LMA removal is 1.5 ng/mL.</description>
    <arm_group_label>ultiva,remifentanil,opioid,analgesic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I-II status

          -  aged 18-60 years old

          -  presenting for ureterorenoscopy

        Exclusion Criteria:

          -  history of hypertension

          -  asthma and chronic obstructive lung disease

          -  recent respiratory tract infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jülide Ergil, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ministry of Health Dıskapi Yildirim Beyazit Training and Research Hospital, Anesthesiology 1.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alp Alptekin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ministry of Health Diskapi Yildirim Beyazit Training and Research Hospital, Anesthesiology 1</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nihan Aktürk, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ministry of Health Diskapi Yildirim Beyazit Training and Research Hospital , Anesthesiology 1</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haluk Gümüs, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ministry of Health Diskapi Yildirim Beyazit Training and Research Hospital, Anesthesiology 1</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ministry of Health Diskapi Yildirim Beyazit Research and Training Hospital departement of 1. Anesthesiology</name>
      <address>
        <city>Ankara</city>
        <zip>06110</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Nho JS, Lee SY, Kang JM, Kim MC, Choi YK, Shin OY, Kim DS, Kwon MI. Effects of maintaining a remifentanil infusion on the recovery profiles during emergence from anaesthesia and tracheal extubation. Br J Anaesth. 2009 Dec;103(6):817-21. doi: 10.1093/bja/aep307. Epub 2009 Oct 28.</citation>
    <PMID>19864308</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2011</study_first_submitted>
  <study_first_submitted_qc>February 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2011</study_first_posted>
  <results_first_submitted>January 30, 2012</results_first_submitted>
  <results_first_submitted_qc>May 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 18, 2012</results_first_posted>
  <last_update_submitted>June 15, 2012</last_update_submitted>
  <last_update_submitted_qc>June 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Diskapi Teaching and Research Hospital</investigator_affiliation>
    <investigator_full_name>derya özkan</investigator_full_name>
    <investigator_title>MD consultant</investigator_title>
  </responsible_party>
  <keyword>Remifentanil</keyword>
  <keyword>Laryngeal mask airway removal</keyword>
  <keyword>Hemodynamic changing</keyword>
  <keyword>Infusion</keyword>
  <keyword>Ureterorenoscopy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ultiva,Remifentanil,Opioid,Analgesic</title>
          <description>Remifentanil:1.5ng/ml remifentanil infusion maintained at the end of the surgery</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Control:Remifentanil stopped at the end of the surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20">One patient excluded from the study because of the failure while performing uretero-renoscopy</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>the failure while performing URS</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ultiva,Remifentanil,Opioid,Analgesic</title>
          <description>Remifentanil:1.5ng/ml remifentanil infusion maintained at the end of the surgery</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Control:Remifentanil stopped at the end of the surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="13"/>
                    <measurement group_id="B2" value="38" spread="12"/>
                    <measurement group_id="B3" value="39" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Smooth cLMA Removal Condition (Score 1)</title>
        <description>cLMA removal was accepted as successful (score 1) if none of the complications coughing, teeth clenching, gross purposeful movements, breath holding, laryngospasm, and desatura- tion to SpO2\90% was observed. If any of these compli- cations was observed it was regarded as unsuccessful (score 2)</description>
        <time_frame>At the end of the surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Remifentanil Group</title>
            <description>remifentanil group (group R) TCI effect-site of remifentanil at 1.5 ng/ml was continued until cLMA removal</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Remifentanil stopped at the and of the surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Smooth cLMA Removal Condition (Score 1)</title>
          <description>cLMA removal was accepted as successful (score 1) if none of the complications coughing, teeth clenching, gross purposeful movements, breath holding, laryngospasm, and desatura- tion to SpO2\90% was observed. If any of these compli- cations was observed it was regarded as unsuccessful (score 2)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The incidence of complications on removal of the cLMA has been reported 54 % in awake patients group A power analysis indicated that a minimum 16 patients in each group were required to demonstrate a difference that 50% reduction the complications (a power of 80% and α error 0.05).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Statistical analyses were performed x2 test or Mann Whitney U test as approriate. A p value of &lt;0.05 was considered statistically significant.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the surgery</time_frame>
      <desc>serious and/or other [non-serious] adverse events were not collected/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Remifentanil Group</title>
          <description>remifentanil group (group R) TCI effect-site of remifentanil at 1.5 ng/ml was continued until cLMA removal</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Remifentanil stopped at the end of the surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitation of our study is age and ASA status of the included patients’. The relatively older or ASA status III,IV population may interfere the effect-site concentration TCI of remifentanil</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Derya Özkan MD</name_or_title>
      <organization>Ministry of Health Diskapi Yildirim Beyazit Training and Research Hospital 1. Anesthesiology</organization>
      <phone>0903125962553</phone>
      <email>derya_z@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

